Lifelong Management Of Hypertension (developments In Cardiovascular Medicine)

In the thirty years since the advent of efTective pharmacologic treatment for hypertension, the world ofthe hypertensive has been transformed beyond recog­ nition. The first change involved only malignant hypertensives with enough residual renal parenchyma to survive. Such a hypertensive could trade inevitable renal failure - unless an intracerebral bleed occurred first - for a rigid regimen which prevented his blood pressure from destroying him but which was asso­ ciated with nearly intolerable side effects. Over the next 20 years, increasing numbers of patients with hypertension of decreasing severity were treated with drugs that had fewer and fewer side effects. In 1970, with the medical world finally ready to accept the concept, the well-known Veterans Administration Study demonstrated that morbidity and mortality could be diminished in mode­ rately hypertensive patients by antihypertensive therapy that had minimal side effects. As a result there has been a major attempt to bring everyone with elevated blood pressure under lifelong pharmacologic control. It is difficult, however, to know what levels ofblood pressure deserve treatment; many who, when therapy first became available, would not have even been considered hypertensive are now candidates for treatment. The lower the pressure, the larger the potential population to be treated, but the smaller the individual risk and hence the smaller the possible benefit. The point where decades of diminished quaiity of life from treatment begins to outweigh a possible late-life complication is yet to be de­ termined. Front Matter....Pages I-X Introduction....Pages 1-5 Epidemiology of mild hypertension....Pages 6-21 Childhood precursors of adult hypertension....Pages 22-45 Therapeutic decisons in management of borderline hypertension....Pages 46-56 Salt, diuretics and resistance to treatment....Pages 57-72 Autonomic drugs used in the treatment of the hypertensive patient with particular reference to beta-receptor blocking agents....Pages 73-89 Vasodilators and their association with remission....Pages 90-108 Nonpharmacologic treatment of hypertension....Pages 109-115 The enigma of mild hypertension: how much treatment?....Pages 116-136 Antihypertensive drug interactions....Pages 137-149 Complications of hypertension and their relation to therapy....Pages 150-170 Heart failure and hypertension....Pages 171-180 Antiplatelet drugs....Pages 181-202 Pregnancy, oral contraceptives and hypertension....Pages 203-228 Systolic hypertension in the elderly....Pages 229-239 Paramedical personnel and adherence to antihypertensive regimens....Pages 240-249 Economics of hypertension....Pages 250-260 Back Matter....Pages 261-268